A new study found that Zyprexa (olanzapine) was associated with lower risk of mortality than placebo in the Medicaid-insured population and the Medicaid-noninsured population. The study also found a lower rate of death from cardiovascular disease (CVD) with Zyprexa compared to placebo, although this effect was more pronounced among Medicaid patients than those at the general population. In a large population-based cohort, the risk of CVD with Zyprexa was 2.6 times greater for Medicaid patients than for those at the general population. This finding was consistent with the findings of a meta-analysis that found similar results with placebo-controlled trials. The study also found that a higher risk of CVD persisted even after a year of follow-up for Medicaid patients compared to those on a placebo. This finding is consistent with a study that compared a different formulation of Zyprexa for treatment of schizophrenia. A study in the New England Journal of Medicine also found an increased risk of CVD with long-term use of Zyprexa. Overall, the study found that Zyprexa was associated with lower risk of CVD in the Medicaid-insured population and the Medicaid-noninsured population.
Drug-related safety issuesA new study published in the Journal of the American Medical Association and published in JAMA Internal Medicine in October 2020 found that a combination of ZYPREXA and other medications, including Zyprexa (olanzapine), increased the risk of major cardiovascular (CV) events. The study found that the combination of ZYPREXA and other medications (i.e., a similar number of drugs in the class) led to a greater risk of a higher percentage of death in patients who developed serious cardiovascular-related events. The increase in the risk of serious cardiovascular events occurred in the second year of treatment, when the combination of ZYPREXA and other medications was more widely prescribed. A meta-analysis found that a higher risk of CV-related events was associated with a lower incidence of serious CV-related events. The increased risk of serious CV-related events was also associated with a higher incidence of a higher number of patients with CV-related death. The risk of serious CV-related death was increased in the first year of therapy, when ZYPREXA and other medications were most commonly prescribed.
A study published in the Journal of the American Medical Association and published in JAMA Internal Medicine in July 2020 found that the combination of ZYPREXA and other medications (i.e., a similar number of drugs in the class) led to a greater risk of fatal CV-related death. This was the second study to examine the combined use of ZYPREXA and other medications in this class. The study found that the combination of ZYPREXA and other medications (i.e., a similar number of drugs in the class) led to a greater risk of a higher percentage of death in patients who developed serious CV-related events.
The study found that the use of a combination of ZYPREXA and other medications (i.e., a similar number of drugs in the class) led to a greater risk of death in patients who developed serious CV-related events. The increased risk of CV-related death was associated with a higher incidence of serious CV-related death. Overall, the study found that the risk of CV-related death was increased in patients who used the combination of ZYPREXA and other medications.
A study published in the Journal of the American Medical Association and published in JAMA Internal Medicine in September 2020 found that the combination of ZYPREXA and other medications (i.e., a similar number of drugs in the class) led to a greater risk of a higher percentage of death in patients who developed serious CV-related events. The increased risk of CV-related death was associated with a higher incidence of a higher number of patients with CV-related death.
In a study published in JAMA Internal Medicine in September 2020, the researchers evaluated the effect of the combination of ZYPREXA and other medications on the risk of serious heart-related death. The researchers compared patients who had already suffered a heart-related death (death by coronary artery bypass graft, bypass surgery, bypass-related death, or heart attack) to those who had not suffered the heart-related death. The researchers found that the use of ZYPREXA and other medications was associated with a lower incidence of fatal heart-related events. The increased risk of fatal heart-related events was associated with a higher incidence of serious heart-related death. Overall, the researchers found that the risk of fatal heart-related events was increased in patients who used the combination of ZYPREXA and other medications.
Olanzapine, also known by its brand name Zyprexa, is a second-generation antipsychotic medication primarily used to treat schizophrenia, bipolar disorder, and major depressive disorder. Its primary function is to stabilize mood and reduce psychotic symptoms associated with these conditions. However, like all second-generation antipsychotic medications, it may also cause extrapyramidal symptoms (EPS), including trouble sleeping, involuntary motor activity, increased sweating, and tremors. This article explores how olanzapine affects EPS, how it works, its potential benefits, and how it may improve your mental health.
Olanzapine is an antipsychotic medication primarily used to treat schizophrenia, bipolar disorder, and major depressive disorder. Unlike other antipsychotic medications, olanzapine is a short-acting, long-acting antipsychotic that works by changing the levels of certain chemicals in the brain, including dopamine and serotonin receptors.
Olanzapine works by increasing the effects of serotonin (a neurotransmitter that affects mood, behavior, and cognition). It may be prescribed to individuals with the following conditions:
It is crucial to understand that olanzapine is not a cure for these conditions. It is a symptomatic treatment option that helps manage symptoms and improve functioning in patients with these conditions.
To minimize the risk of extrapyramidal symptoms and EPS symptoms, take olanzapine exactly as prescribed by your healthcare provider. Your healthcare provider will likely begin with a lower dose and gradually increase it as needed.
Taking the medication with food or milk can reduce the risk of these side effects. However, it is important to note that this medication may not be suitable for everyone. To ensure the safe and effective use of olanzapine, it is important to follow the prescribed dosage and treatment plan provided by your healthcare provider.
Olanzapine may cause some common side effects. However, these are generally mild and tend to subside as your body adjusts to the medication. If any of these side effects persist or worsen, contact your healthcare provider immediately.
Less common side effects may include:
These side effects are usually temporary and subside as your body adjusts to the medication. However, it is important to be aware of them and report them to your healthcare provider immediately.
To reduce the risk of EPS symptoms, it is crucial to consider the following factors:
If you have developed any of these symptoms, it is essential to seek medical attention immediately.
Olanzapine may offer some benefits for treating various conditions. For example, it may help reduce the symptoms of bipolar disorder and reduce hallucinations or delusions associated with bipolar disorder.
The medication may also have antidepressant effects.
ZYPREXA is a medication used to treat schizophrenia and bipolar disorder. It belongs to a group of medications called antipsychotics. It works by helping to restore the balance of certain natural substances in the brain.
It may take a few weeks for ZYPREXA to see a significant improvement in symptoms.
Take ZYPREXA exactly as prescribed and only take it when your doctor tells you to.
It's important to remember that ZYPREXA can cause side effects. Common ZYPREXA side effects include dry mouth, constipation, dizziness, and weight gain. These side effects are usually mild and temporary.
If you experience any serious side effects, such as suicidal thoughts or actions, seek medical attention immediately.
The most common side effects of ZYPREXA include dry mouth, constipation, dizziness, loss of appetite, weight gain, fatigue, nausea, vomiting, dry mouth, difficulty sleeping, and changes in heart rate.
If you experience any side effects that persist or worsen, seek medical attention immediately.
In some cases, ZYPREXA may be used off-label for other medical conditions. It's important to talk to your doctor before taking ZYPREXA if you are on any form of any medication, including, or if you are taking any other form of or other forms of the following:
If you are prescribed ZYPREXA and have thoughts of suicide, contact your doctor immediately.
Do not take ZYPREXA if:
Tell your doctor immediately if you notice any of these symptoms:
If you have bipolar disorder and taking ZYPREXA, it is important to tell your doctor about all the medications you are currently taking, including prescription and over-the-counter medications, vitamins, and herbal supplements. Your doctor may also recommend you take a multivitamin supplement daily.
The following are some other precautions to keep in mind when taking ZYPREXA:
Do not stop taking ZYPREXA without talking to your doctor first. Stopping suddenly can have serious consequences. If you do not become dependent on ZYPREXA, talk to your doctor about gradually decreasing your dose.
If you are not sure if it is safe to take ZYPREXA and if your doctor has prescribed it, ask your doctor.
If you have any questions or concerns about taking ZYPREXA, talk to your doctor right away.
If you are taking any other medications, check with your doctor before starting or stopping any new medications, including prescription and over-the-counter medications.
Published on April 28, 2025
Zyprexa® (olanzapine) is an antipsychotic medication that is used to treat major depressive disorder (MDD). It works by affecting certain chemicals in the brain that are involved in mood regulation. Zyprexa® is approved for use in adults, children and adolescents 6 years of age and older. It is available in various forms, including tablets, extended release tablets, and immediate-release tablets. Zyprexa® is typically prescribed as an adjunct to other medications and therapies for managing symptoms of mental health disorders. It is available in various strengths, including 10 mg and 20 mg tablets, and is available in various strengths, including extended release tablets, extended release tablets, and injectable injectable tablets. Zyprexa® can be prescribed off-label for off-label uses, and it is sometimes used as a monotherapy in combination with other medications.
Zyprexa® (olanzapine) is an antipsychotic medication that works by affecting certain chemicals in the brain that are involved in mood regulation. It is approved for use in adults, children 6 years of age and older, and it is available in various strengths, including 10 mg and 20 mg tablets. It is available in various forms, including 10 mg and 20 mg tablets, and it is available in various strengths, including extended release tablets, extended release tablets, and injectable injectable tablets. Zyprexa® is sometimes used off-label for off-label uses, and it is sometimes used as a monotherapy in combination with other medications and therapies.
Zyprexa® (olanzapine) is an antipsychotic medication that is used to treat symptoms of schizophrenia. Zyprexa® is approved for use in adults, children and adolescents 6 years of age and older, and it is available in various strengths, including 10 mg and 20 mg tablets. Zyprexa® can be prescribed off-label for off-label uses, and it is sometimes used as a monotherapy in combination with other medications and therapies.
Zyprexa® (olanzapine) is an antipsychotic medication that is used to treat certain conditions.
Stade de France Pharmacy